JCM
ADMA icon

Janney Capital Management’s ADMA Biologics ADMA Stock Holding History

Janney Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$271K Buy
+14,832
New +$250K 0.02% 228

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.82B AUM 73.38% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Janney Capital Management's ADMA Position: Q4 2025 in Review

Janney Capital Management opened a new position in ADMA Biologics (ADMA) in Q4 2025: 14,832 shares worth $271K. The stake represents 0.02% of the portfolio and ranks #228 among its holdings.

356 funds tracked by Wall St. Rank hold ADMA as of Q4 2025.

  • Janney Capital Management held 14,832 shares of ADMA Biologics worth $271K as of Q4 2025.
  • ADMA Biologics was a new Janney Capital Management position in Q4 2025.
  • ADMA Biologics made up 0.02% of Janney Capital Management's portfolio in Q4 2025, its #228 holding.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2025.

Based on Janney Capital Management's 13F filing for Q4 2025, filed 11 Feb 2026.